Novartis Holly Springs facility becomes first US pandemic-ready site licensed by the FDA to produce cell-culture influenza vaccines

Cell-culture technology is a modern alternative to manufacture influenza vaccines without chicken eggs, with potential to rapidly respond to a pandemic[1] Flucelvax®, an FDA-approved antibiotic- and preservative-free seasonal flu vaccine, will be manufactured at this site for the US market[2] Licensure marks milestone in Novartis’ public-private partnership to improve US capabilities to respond to seasonal epidemics and emerging public health …

An interview with Dr Rappuoli on the vaccine industry

As part of a series of interviews conducted with leading speakers of the World Vaccine Congress in Washington D.C., Terrapinn were delighted to sit down with Dr Rino Rappuoli, Global Head of Vaccines Research at Novartis Vaccines and Diagnostics. The conversation delved into the future role of big pharma in vaccines, how to deal with anti-vaccine rhetoric and what big …

Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza

Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza Cell-culture technology, an alternative to traditional egg-based production, is the most significant advancement in influenza vaccine manufacturing in more than 40 years[1] Flucelvax is the only influenza vaccine of its kind in the US and does not contain any preservatives, such as …